# EDGAR Filing Document

**Accession Number:** 0001304161
**File Stem:** 0001654954-23-001436
**Filing Date:** 2023-2
**Character Count:** 7974
**Document Hash:** 675ec9f1c27d7cad51470706ae48d4a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001436.hdr.sgml**: 20230207

**ACCESSION NUMBER**: 0001654954-23-001436

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230207

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharma-Bio Serv, Inc.
- **CENTRAL INDEX KEY:** 0001304161
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **IRS NUMBER:** 200653570
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50956
- **FILM NUMBER:** 23595972

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646
- **BUSINESS PHONE:** 787-278-2709

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAWRENCE CONSULTING GROUP INC
- **DATE OF NAME CHANGE:** 20040923

?xml version="1.0" encoding="utf-8"?pbsv_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 7, 2023**

---

| |
|:---|
| **Pharma-Bio Serv, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-50956** | **20-0653570** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer <br>Identification No.) |

---

---

| | |
|:---|:---|
| **6 Road 696, Dorado, Puerto Rico** | **00646** |
| (Address of Principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code **(787) 278-2709**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On February 7, 2023, Pharma-Bio Serv, Inc. issued a press release announcing that it has retained ACP Capital Markets LLC for investment banking and M&A advisory services.

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](pbsv_ex991.htm) | [Press Release, dated February 7, 2023.](pbsv_ex991.htm) |
| 104 | Cover page Interactive Data File (embedded within the Inline XBRL document). |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PHARMA-BIO SERV, INC. | PHARMA-BIO SERV, INC. |
| Date: February 7, 2023  | By:  | /s/ Pedro J. Lasanta |
|  |  | Pedro J. Lasanta  |
|  |  | Chief Financial Officer, Vice President Finance and Administration and Secretary |

---

3<br>

## Exhibit 99.1

**EXHIBIT 99.1**

**Pharma-Bio Serv Retains Investment Banking Firm**

**ACP Capital to Provide Investment Banking and**

**M&A Advisory Services**

**DORADO, PUERTO RICO / ACCESSWIRE / February 7, 2023 /** Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, announced today that it has retained ACP Capital Markets LLC ("ACP") for investment banking and M&A advisory services.

ACP Capital Markets is a specialized investment bank focused on capital markets and advisory assignments. ACP's capital markets unit specializes in private equity and debt placements while its M&A and Advisory practice is globally focused, covering both public and private market issuers. Securities placements are conducted through its dedicated broker-dealer entity, Aldwych Securities LLC, a FINRA/SEC registered entity.

Victor Sanchez, CEO of Pharma-Bio Serv said, "I am delighted to have the talented investment banking team at ACP working with us. They have the M&A experience and expertise necessary to assist us in strategically growing our company through potential acquisitions and exploring alternatives as part of our ongoing efforts to maximize shareholder value while improving and expanding our portfolio of services for our clients."

"We are delighted to work with the Pharma-Bio Serv leadership team to help advance the opportunities that are before the company and to assist the company's transformation and growth," stated Sagiv Shiv, Head of M&A and Advisory Services at ACP.

**About Pharma-Bio Serv, Inc.**

Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

**Forward-Looking Statements**

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause Pharma-Bio Serv's actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2022, and in its other filings with the Securities and Exchange Commission, which filings are available on <u>www.sec.gov</u>. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

**Company Contact:**

Pedro J. Lasanta

Chief Financial Officer

787 278 2709

**SOURCE:** Pharma-Bio Serv Inc.